

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32628 A1

(51) International Patent Classification⁷: **C07D 231/14**,
A61P 7/02, C07D 401/12, 249/10, 403/12

[US/US]; 425 Brentford Road, Kennett Square, PA 19348 (US).

(21) International Application Number: PCT/US00/30209

(74) Agent: **ROPER, David, J.**; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(22) International Filing Date:

2 November 2000 (02.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/163,268

3 November 1999 (03.11.1999)

US

(81) Designated State (*national*): US.

(71) Applicant (*for all designated States except US*): **DU PONT PHARMACEUTICALS COMPANY** [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19805 (US).

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— With international search report.


— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(72) Inventor; and


(75) Inventor/Applicant (*for US only*): **PINTO, Donald, J., P.**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: CYANO COMPOUNDS AS FACTOR Xa INHIBITORS




(Ia)



(Ib)



(Ic)



(Id)

(57) Abstract: The present application describes inhibitors of factor Xa which are cyano-pyrazole, cyano-triazole, cyano-imidazole, and cyano-pyrrole compounds of Formulae (Ia), (Ib), (Ic), and (Id): or pharmaceutically acceptable salt forms thereof.

TITLE

CYANO COMPOUNDS AS FACTOR Xa INHIBITORS

5

FIELD OF THE INVENTION

This invention relates generally to cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds which are inhibitors of trypsin-like serine
 10 protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.


15

BACKGROUND OF THE INVENTION

Inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system. Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable
 20 therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors.

WO98/28269 describes factor Xa inhibitors of the formula:


25



30


wherein ring M can be a variety of N-containing heterocycles including pyrrole, pyrazole, imidazole, and triazole and D is substituted meta or para to G on E. However, WO98/28269 does not disclose cyano-substituted compounds like those of
 the present invention.

WO98/57951 describes factor Xa inhibitors of the formula:




wherein ring D is selected from $-\text{CH}_2\text{N}=\text{CH}-$, $-\text{CH}_2\text{CH}_2\text{N}=\text{CH}-$, a 5-6 membered aromatic system containing from 0-2 heteroatoms selected from the group N, O, and S, ring E contains 0-2 N atom and M is a variety of rings including pyrrole, pyrazole, imidazole, and triazole. WO98/57951 does not, however, disclose cyano-substituted compounds like those of the present invention.

WO98/57937 describes factor Xa inhibitors of the formula:



wherein ring D is phenyl or pyridyl and M is a variety of rings including pyrrole, pyrazole, imidazole, and triazole. However, WO98/57937 does not disclose cyano-substituted compounds like those of the present invention.

PCT/US98/26427 describes factor Xa inhibitors of the formula:



wherein ring M is a variety of rings including pyrrole, pyrazole, imidazole, and triazole and D is substituted ortho to G on E. However, PCT/US98/26427 does not disclose cyano-substituted compounds like those of the present invention.

SUMMARY OF THE INVENTION

One object of the present invention is to provide novel cyano-pyrazole and cyano-triazole compounds which are useful

as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof.


It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to provide novel compounds for use in therapy.

It is another object of the present invention to provide the use of novel compounds for the manufacture of a medicament for the treatment of a thromboembolic disorder.


These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formulae Ia, Ib, Ic, and Id:



or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, D, E, R^{1a}, and Z are defined below, are factor Xa inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[1] Thus, in an embodiment, the present invention provides novel compounds of formulae Ia, Ib, Ic, and Id:



or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

10 D is selected from $C(=NR^8)NR^7R^9$, $C(O)NR^7R^8$, NR^7R^8 , and $CH_2NR^7R^8$, provided that D is substituted meta or para to ring M on E;

E is phenyl substituted with 1 R or pyridyl substituted with 1 R;

15

R is selected from H, Cl, F, OR^3 , CH_3 , CH_2CH_3 , OCF_3 , and CF_3 ;

20

Z is selected from $C(O)$, $CH_2C(O)$, $C(O)CH_2$, $NHC(O)$, and $C(O)NH$, provided that Z does not form a N-N bond with group A;

R^{1a} is selected from H, $-(CH_2)_r-R^{1'}$, $-CH=CH-R^{1'}$, $NCH_2R^{1''}$, $OCH_2R^{1''}$, $SCH_2R^{1''}$, $NH(CH_2)_2(CH_2)_tR^{1'}$, $O(CH_2)_2(CH_2)_tR^{1'}$, and $S(CH_2)_2(CH_2)_tR^{1'}$;

25

$R^{1'}$ is selected from H, C_{1-3} alkyl, F, Cl, Br, I, $-CN$, $-CHO$, $(CF_2)_rCF_3$, $(CH_2)_rOR^2$, NR^2R^{2a} , $C(O)R^{2c}$, $OC(O)R^2$, $(CF_2)_rCO_2R^{2c}$, $S(O)_pR^{2b}$, $NR^2(CH_2)_rOR^2$, $CH(=NR^{2c})NR^2R^{2a}$, $NR^2C(O)R^{2b}$, $NR^2C(O)NHR^{2b}$, $NR^2C(O)_2R^{2a}$, $OC(O)NR^{2a}R^{2b}$, $C(O)NR^2R^{2a}$, $C(O)NR^2(CH_2)_rOR^2$, $SO_2NR^2R^{2a}$, $NR^2SO_2R^{2b}$, C_{3-6}

30

carbocyclic residue substituted with 0-2 R^{4a} , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a} ;

5

$R^{1''}$ is selected from H, $\text{CH}(\text{CH}_2\text{OR}^2)_2$, $\text{C}(\text{O})\text{R}^{2c}$, $\text{C}(\text{O})\text{NR}^2\text{R}^{2a}$, $\text{S}(\text{O})\text{R}^{2b}$, $\text{S}(\text{O})_2\text{R}^{2b}$, and $\text{SO}_2\text{NR}^2\text{R}^{2a}$;

10

R^2 , at each occurrence, is selected from H, CF_3 , C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , a C_{3-6} carbocyclic- CH_2 - residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

15

R^{2a} , at each occurrence, is selected from H, CF_3 , C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

20

R^{2b} , at each occurrence, is selected from CF_3 , C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

25

R^{2c} , at each occurrence, is selected from CF_3 , OH, C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

30

alternatively, R^2 and R^{2a} , together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R^{4b} and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

R^3 , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3a} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3b} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3c} , at each occurrence, is selected from C_{1-4} alkyl, and phenyl;

A is selected from:

C_{3-10} carbocyclic residue substituted with 0-2 R^4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^4 ;

B is selected from:

$X-Y$, NR^2R^{2a} , $C(=NR^2)NR^2R^{2a}$, $NR^2C(=NR^2)NR^2R^{2a}$,

C_{3-10} carbocyclic residue substituted with 0-2 R^{4a} , and 5-10 membered heterocyclic system containing from 1-4

heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a} ;

X is selected from C_{1-4} alkylene, $-CR^2(CR^2R^{2b})(CH_2)_t-$, $-C(O)-$, $-C(=NR^{1''})-$, $-CR^2(NR^{1''}R^2)-$, $-CR^2(OR^2)-$, $-CR^2(SR^2)-$, $-C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)-$, $-S(O)_p-$, $-S(O)_pCR^2R^{2a}-$,

$-\text{CR}^2\text{R}^{2a}\text{S}(\text{O})_p-$, $-\text{S}(\text{O})_2\text{NR}^2-$, $-\text{NR}^2\text{S}(\text{O})_2-$, $-\text{NR}^2\text{S}(\text{O})_2\text{CR}^2\text{R}^{2a}-$,
 $-\text{CR}^2\text{R}^{2a}\text{S}(\text{O})_2\text{NR}^2-$, $-\text{NR}^2\text{S}(\text{O})_2\text{NR}^2-$, $-\text{C}(\text{O})\text{NR}^2-$, $-\text{NR}^2\text{C}(\text{O})-$,
 $-\text{C}(\text{O})\text{NR}^2\text{CR}^2\text{R}^{2a}-$, $-\text{NR}^2\text{C}(\text{O})\text{CR}^2\text{R}^{2a}-$, $-\text{CR}^2\text{R}^{2a}\text{C}(\text{O})\text{NR}^2-$,
 $-\text{CR}^2\text{R}^{2a}\text{NR}^2\text{C}(\text{O})-$, $-\text{NR}^2\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})\text{NR}^2-$, $-\text{NR}^2\text{C}(\text{O})\text{NR}^2-$,
5 $-\text{NR}^2-$, $-\text{NR}^2\text{CR}^2\text{R}^{2a}-$, $-\text{CR}^2\text{R}^{2a}\text{NR}^2-$, O , $-\text{CR}^2\text{R}^{2a}\text{O}-$, and
 $-\text{OCR}^2\text{R}^{2a}-$;

Y is selected from:

(CH₂)_rNR²R^{2a}, provided that X-Y do not form a N-N, O-N,
 10 or S-N bond,

C₃₋₁₀ carbocyclic residue substituted with 0-2 R^{4a}, and
 5-10 membered heterocyclic system containing from 1-4
 heteroatoms selected from the group consisting of N, O, and
 S substituted with 0-2 R^{4a};

15

R⁴, at each occurrence, is selected from H, =O, (CH₂)_rOR², F,
 Cl, Br, I, C₁₋₄ alkyl, -CN, NO₂, (CH₂)_rNR²R^{2a},
 (CH₂)_rC(O)R^{2c}, NR²C(O)R^{2b}, C(O)NR²R^{2a}, NR²C(O)NR²R^{2a},
 CH(=NR²)NR²R^{2a}, CH(=NS(O)₂R⁵)NR²R^{2a}, NHC(=NR²)NR²R^{2a},
 20 C(O)NHC(=NR²)NR²R^{2a}, SO₂NR²R^{2a}, NR²SO₂NR²R^{2a}, NR²SO₂-C₁₋₄
 alkyl, NR²SO₂R⁵, S(O)_pR⁵, (CF₂)_rCF₃, NCH₂R^{1''}, OCH₂R^{1''},
 SCH₂R^{1''}, N(CH₂)₂(CH₂)_tR^{1'}, (CH₂)₂(CH₂)_tR^{1'}, and
 S(CH₂)₂(CH₂)_tR^{1'};

25 alternatively, one R⁴ is a 5-6 membered aromatic heterocycle
 containing from 1-4 heteroatoms selected from the group
 consisting of N, O, and S;

R^{4a}, at each occurrence, is selected from H, =O, (CH₂)_rOR²,
 30 (CH₂)_r-F, (CH₂)_r-Br, (CH₂)_r-Cl, Cl, Br, F, I, C₁₋₄ alkyl,
 -CN, NO₂, (CH₂)_rNR²R^{2a}, (CH₂)_rC(O)R^{2c}, NR²C(O)R^{2b},
 C(O)NR²R^{2a}, C(O)NH(CH₂)₂NR²R^{2a}, NR²C(O)NR²R^{2a},
 CH(=NR²)NR²R^{2a}, NHC(=NR²)NR²R^{2a}, SO₂NR²R^{2a}, NR²SO₂NR²R^{2a},
 NR²SO₂-C₁₋₄ alkyl, C(O)NHSO₂-C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_pR⁵,
 35 and (CF₂)_rCF₃;

alternatively, one R^{4a} is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R^5 ;

5

R^{4b} , at each occurrence, is selected from H, =O, $(CH_2)_rOR^3$, F, Cl, Br, I, C_{1-4} alkyl, -CN, NO_2 , $(CH_2)_rNR^3R^{3a}$, $(CH_2)_rC(O)R^3$, $(CH_2)_rC(O)OR^{3c}$, $NR^3C(O)R^{3a}$, $C(O)NR^3R^{3a}$, $NR^3C(O)NR^3R^{3a}$, $CH(=NR^3)NR^3R^{3a}$, $NR^3C(=NR^3)NR^3R^{3a}$, $SO_2NR^3R^{3a}$, $NR^3SO_2NR^3R^{3a}$, $NR^3SO_2-C_{1-4}$ alkyl, $NR^3SO_2CF_3$, NR^3SO_2 -phenyl, $S(O)_pCF_3$, $S(O)_p-C_{1-4}$ alkyl, $S(O)_p$ -phenyl, and $(CF_2)_rCF_3$;

10

R^5 , at each occurrence, is selected from CF_3 , C_{1-6} alkyl, phenyl substituted with 0-2 R^6 , and benzyl substituted with 0-2 R^6 ;

15

R^6 , at each occurrence, is selected from H, OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, -CN, NO_2 , $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $NR^2C(O)NR^2R^{2a}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, $SO_2NR^2R^{2a}$, $NR^2SO_2NR^2R^{2a}$, and $NR^2SO_2C_{1-4}$ alkyl;

20

R^7 , at each occurrence, is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{1-6} alkoxy, C_{1-4} alkoxy carbonyl, $(CH_2)_n$ -phenyl, C_{6-10} aryloxy, C_{6-10} aryloxy carbonyl, C_{6-10} arylmethylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkoxy carbonyl, C_{6-10} arylcarbonyloxy C_{1-4} alkoxy carbonyl, C_{1-6} alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C_{1-4} alkoxy carbonyl;

25

R^8 , at each occurrence, is selected from H, C_{1-6} alkyl and $(CH_2)_n$ -phenyl;

30

alternatively, R^7 and R^8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional

heteroatoms selected from the group consisting of N, O, and S;

R⁹, at each occurrence, is selected from H, C₁₋₆ alkyl and
5 (CH₂)_n-phenyl;

n, at each occurrence, is selected from 0, 1, 2, and 3;

m, at each occurrence, is selected from 0, 1, and 2;

10

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3;

15 s, at each occurrence, is selected from 0, 1, and 2; and,

t, at each occurrence, is selected from 0, 1, 2, and 3.

20 [2] In another embodiment, the present invention provides a compound of formula Ic or Id, wherein:

A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R⁴;

25

phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, 30 benzothiofuranyl, indolyl, benzimidazolyl,

35

benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

B is selected from: H, Y, X-Y;

5

X is selected from C₁₋₄ alkylene, -C(O)-, -C(=NR)-, -CR²(NR²R^{2a})-, -C(O)CR²R^{2a}-, -CR²R^{2a}C(O)-, -C(O)NR²-, -NR²C(O)-, -C(O)NR²CR²R^{2a}-, -NR²C(O)CR²R^{2a}-, -CR²R^{2a}C(O)NR²-, -CR²R^{2a}NR²C(O)-, -NR²C(O)NR²-, -NR²-, -NR²CR²R^{2a}-, -CR²R^{2a}NR²-, O, -CR²R^{2a}O-, and -OCR²R^{2a}-;

10

Y is NR²R^{2a}, provided that X-Y do not form a N-N or O-N bond;

alternatively, Y is selected from one of the following

15


carbocyclic and heterocyclic systems which are substituted with 0-2 R^{4a};

cyclopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

25

30

alternatively, Y is selected from the following bicyclic heteroaryl ring systems:



K is selected from O, S, NH, and N; and,

5 s is 0.

[3] In another embodiment, the present invention provide a novel compound wherein;

10

E is phenyl substituted with R or 2-pyridyl substituted with R;

R is selected from H, Cl, F, OCH₃, CH₃, OCF₃, and CF₃;

15

Z is selected from a C(O)CH₂ and C(O)NH, provided that Z does not form a N-N bond with group A;

20

R^{1a} is selected from H, CH₃, CH₂CH₃, Cl, F, CF₃, OCH₃, NR²R^{2a}, S(O)_pR^{2b}, CH₂S(O)_pR^{2b}, CH₂NR²S(O)_pR^{2b}, C(O)R^{2c}, CH₂C(O)R^{2c}, C(O)NR²R^{2a}, and SO₂NR²R^{2a};

A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R⁴; and,

25

B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^{4a};

R^2 , at each occurrence, is selected from H, CH_3 , CH_2CH_3 , cyclopropylmethyl, cyclobutyl, and cyclopentyl;

R^{2a} , at each occurrence, is H or CH_3 ;

5

alternatively, R^2 and R^{2a} , together with the atom to which they are attached, combine to form pyrrolidine substituted with 0-2 R^{4b} ;

10 R^4 , at each occurrence, is selected from OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, and $(CF_2)_rCF_3$;

R^{4a} is selected from C_{1-4} alkyl, CF_3 , $(CH_2)_rOR^2$, $(CH_2)_rNR^2R^{2a}$, $S(O)_pR^5$, $SO_2NR^2R^{2a}$, and 1- CF_3 -tetrazol-2-yl;

15

R^{4b} , at each occurrence, is selected from H, CH_3 , and OH;

R^5 , at each occurrence, is selected from CF_3 , C_{1-6} alkyl, phenyl, and benzyl;

20

X is CH_2 or $C(O)$;

Y is selected from pyrrolidino and morpholino; and,

25 r, at each occurrence, is selected from 0, 1, and 2.

[4] In another embodiment, the present invention provides a novel compound wherein;

30

R^{1a} is absent or is selected from H, CH_3 , CH_2CH_3 , Cl, F, CF_3 , OCH_3 , NR^2R^{2a} , $S(O)_pR^{2b}$, $C(O)NR^2R^{2a}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^2S(O)_pR^{2b}$, $C(O)R^{2c}$, $CH_2C(O)R^{2c}$, and $SO_2NR^2R^{2a}$;

A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and,

5

B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

10

15

[5] In another embodiment, the present invention provides a novel compound selected from the group:

20

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-aminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylsulfonyl-[1,1']-biphen-4-yl))carboxamide;

25

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylaminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

30

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N,N-dimethylaminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N-pyrrolidinomethyl-[1,1']-biphen-4-yl))carboxamide;

35

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N-(3"-hydroxypyrrolidino)methyl-[1,1']-biphen-4-yl))carboxamide;

5 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-aminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

10 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylsulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

15 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylaminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

20 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N,N-dimethylaminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2-fluoro-2'-N-pyrrolidinomethyl-[1,1']-biphen-4-yl))carboxamide;

25 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2-fluoro-2'-N-(3"-hydroxypyrrolidino)methyl-[1,1']-biphen-4-yl))carboxamide;

30 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(pyrrolidinocarbonyl)phenyl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(1"-methylimidazol-2"-yl)phenyl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(2"-
methylimidazolyl)phenyl))carboxamide;

5 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(2"-
(N,N-dimethylamino)imidazolyl)phenyl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(pyrrolidinocarbonyl)phenyl))carboxamide;

10 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(1"-methylimidazol-2"-
yl)phenyl))carboxamide;

15 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(2"-methylimidazolyl)phenyl))carboxamide;
and,

20 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(2"-(N,N-
dimethylamino)imidazolyl)phenyl))carboxamide;

or a pharmaceutically acceptable salt form thereof.

25 In another embodiment, the present invention provides
novel pharmaceutical compositions, comprising: a
pharmaceutically acceptable carrier and a therapeutically
effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt form thereof.

30 In another embodiment, the present invention provides a
novel method for treating or preventing a thromboembolic
disorder, comprising: administering to a patient in need
thereof a therapeutically effective amount of a compound of
formula (I) or a pharmaceutically acceptable salt form
35 thereof.

In another embodiment, the present invention provides novel bicyclic compounds as described above for use in therapy.

5

In another embodiment, the present invention provides the use of novel bicyclic compounds as described above for the manufacture of a medicament for the treatment of a thromboembolic disorder.

10

DEFINITIONS

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically
15 active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds
20 described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric,
25 racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the
30 present invention.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that
35 the substitution results in a stable compound. When a

substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties.

The present invention is intended to include all
5 isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

10 When any variable (e.g., R^6) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^6 , then said group may optionally
15 be substituted with up to two R^6 groups and R^6 at each occurrence is selected independently from the definition of R^6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

20 When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then
25 such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" is intended to include both
30 branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. C_{1-10} alkyl, is intended to include C_1 , C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkyl groups. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl,
35 s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is

intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example $-C_vF_w$ where $v = 1$ to 3 and $w = 1$ to $(2v+1)$).

- 5 Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C_{1-10} alkoxy, is intended
- 10 to include C_1 , C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkoxy groups. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxo, and s-pentoxo. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl,
- 15 cyclobutyl, or cyclopentyl. C_{3-7} cycloalkyl, is intended to include C_3 , C_4 , C_5 , C_6 , and C_7 cycloalkyl groups. Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point
- 20 along the chain, such as ethenyl and propenyl. C_{2-10} alkenyl, is intended to include C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkenyl groups. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in
- 25 any stable point along the chain, such as ethynyl and propynyl. C_{2-10} alkynyl, is intended to include C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkynyl groups.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to

30 represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or

13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl.

As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" or "heteroaryl" is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heterotams independently selected from the group consisting of N, NH, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridoazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, benztriazolyl,

benzisoxazolyl, oxindolyl, benzoxazoliny, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

The phrase "pharmaceutically acceptable" is employed
5 herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or
10 complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts
15 thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the
20 conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric,
25 sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-
30 acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical
35 methods. Generally, such salts can be prepared by reacting

the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc...) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers which release an active parent drug of the present invention *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention. Preferred prodrugs are amidine prodrugs wherein D is $C(=NR^7)NH_2$ or its tautomer $C(=NH)NHR^7$ and R^7 is selected from OH, C_{1-4} alkoxy, C_{6-10} aryloxy, C_{1-4} alkoxycarbonyl, C_{6-10} aryloxycarbonyl, C_{6-10}

arylmethylcarbonyl, C₁₋₄ alkylcarbonyloxy C₁₋₄
alkoxycarbonyl, and C₆₋₁₀ arylcarbonyloxy C₁₋₄
alkoxycarbonyl. More preferred prodrugs are where R⁷ is OH,
methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and
5 methylcarbonyloxymethoxycarbonyl.

"Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction
mixture, and formulation into an efficacious therapeutic
10 agent.

"Substituted" is intended to indicate that one or more
hydrogens on the atom indicated in the expression using
"substituted" is replaced with a selection from the
indicated group(s), provided that the indicated atom's
15 normal valency is not exceeded, and that the substitution
results in a stable compound. When a substituent is keto
(i.e., =O) group, then 2 hydrogens on the atom are replaced.


"Therapeutically effective amount" is intended to
include an amount of a compound of the present invention or
20 an amount of the combination of compounds claimed effective
to inhibit factor Xa. The combination of compounds is
preferably a synergistic combination. Synergy, as described
for example by Chou and Talalay, *Adv. Enzyme Regul.* **1984**,
22, 27-55, occurs when the effect (in this case, inhibition
25 of factor Xa) of the compounds when administered in
combination is greater than the additive effect of the
compounds when administered alone as a single agent. In
general, a synergistic effect is most clearly demonstrated
at suboptimal concentrations of the compounds. Synergy can
30 be in terms of lower cytotoxicity, increased antiviral
effect, or some other beneficial effect of the combination
compared with the individual components.

SYNTHESIS

The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention
5 can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The
10 reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent
15 with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major
20 consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained
25 practitioner is Greene and Wuts (*Protective Groups In Organic Synthesis*, Wiley and Sons, **1991**). All references cited herein are hereby incorporated in their entirety herein by reference.


The cyano-substituted compounds of the present
30 invention can be prepared as described in Scheme 1 (wherein D in D-E-NHNH₂ is a cyano group).

Scheme 1



The cyano-substituted compounds of the present
 5 invention can also be prepared as described in Scheme 2
 (wherein D in D-E-NHNH₂ is a cyano group).

Scheme 2



3-Cyano-1,2,4-triazoles of the present invention can be prepared from their corresponding 3-alkoxycarbonyl-1,2,4-triazoles by modifying the alkoxy carbonyl group as shown in Schemes 1 and 2. 3-Alkoxycarbonyl-1,2,4-triazoles can be prepared as shown in Scheme 29 in WO98/28269.

The compounds of the present invention have a group "A-B". Preparations of the "A-B" moieties can follow the same methods described in U.S. 5,886,191, U.S. 5,925,635, WO97/23212, WO97/30971, WO98/06694, WO98/28269, WO98/28282, WO98/57934, WO98/57937, WO98/57951, WO99/12903, and WO99/32454; the contents of which are incorporated herein by reference.

UTILITY

The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic

disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin.

The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA that was monitored spectrophotometrically by measuring the increase in absorbance at 405 nm. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, K_i .

Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 % PEG 8000. The Michaelis constant, K_m , for substrate hydrolysis was determined at 25°C using the method of Lineweaver and Burk. Values of K_i were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate K_i values:

$$(v_0 - v_s) / v_s = I / (K_i (1 + S / K_m))$$

where:

v_o is the velocity of the control in the absence of inhibitor;

v_s is the velocity in the presence of inhibitor;

I is the concentration of inhibitor;

5 K_i is the dissociation constant of the enzyme:inhibitor complex;

S is the concentration of substrate;

K_m is the Michaelis constant.

Compounds tested in the above assay are considered to
10 be active if they exhibit a K_i of ≤ 10 μM . Preferred compounds of the present invention have K_i 's of ≤ 1 μM . More preferred compounds of the present invention have K_i 's of ≤ 0.1 μM . Even more preferred compounds of the present invention have K_i 's of ≤ 0.01 μM . Still more preferred
15 compounds of the present invention have K_i 's of ≤ 0.001 μM .

The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg
20 i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing that contains a piece of silk thread. Blood will flow from the femoral
25 artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p.,
30 s.c., or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose that produces 50% inhibition of thrombus formation) are estimated by linear regression.

The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.

Some compounds of the present invention can be shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. *In vitro* inhibition constants were determined by the method described by Kettner et al. in *J. Biol. Chem.* **265**, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238

(Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm that arises owing to substrate hydrolysis.

Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk.

The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.

The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.

The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and

piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicylic acid or ASA), and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including

5 pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include IIb/IIIa antagonists, thromboxane-A₂-receptor antagonists and
10 thromboxane-A₂-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.

The term thrombin inhibitors (or anti-thrombin agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated
15 processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in
20 the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boro-peptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof.

25 Boroarginine derivatives and boro-peptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal α -aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiuronium analogs thereof. The term hirudin, as used herein, includes
30 suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boro-peptide thrombin inhibitors include compounds described in Kettner et al., U.S. 5,187,157 and EP 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other
35 suitable boroarginine derivatives and boro-peptide thrombin

inhibitors include those disclosed in W092/07869 and EP 471,651 A2, the disclosures of which are hereby incorporated herein by reference.

5 The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein,
10 refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in EP 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the
15 latter also being referred to herein as prourokinase.

Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of
20 lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.

The compounds of the present invention are also useful as standard or reference compounds, for example as a quality
25 standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay
30 to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or

protocols, compounds according to the present invention could be used to test their effectiveness.

The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present.

Dosage and Formulation

The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective

amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.

By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically

acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable

5 binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms
10 include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

15 The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine,
20 or phosphatidylcholines.

Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol,
25 polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid,
30 polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets.

Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

5 A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

10 Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100
15 milligrams of the active ingredient. The capsules should be washed and dried.

Tablets

Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient,
20 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

25 Injectable

A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium
30 chloride and sterilized.

Suspension

An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl

cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may
5 be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage
10 unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25
15 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight.

20 Where the compounds of Formula I are administered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the
25 thrombolytic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.

Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily
30 dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.

Particularly when provided as a single dosage unit, the
35 potential exists for a chemical interaction between the

combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material that affects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.







These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments that are given for illustration of the invention and are not intended to be limiting thereof.

The following tables contain representative examples of the present invention. Each entry in the table is to be paired with each formula at the start of the table. For example, example 1 in Table 1 is to be paired with each of

5 the formulae of Table 1.

Table 1



Ex#	R ^{1a}	B
1.	H	2-(aminosulfonyl)phenyl
2.	H	2-(methylaminosulfonyl)phenyl
3.	H	1-pyrrolidinocarbonyl
4.	H	2-(methylsulfonyl)phenyl
5.	H	2-(N,N-dimethylaminomethyl)phenyl
6.	H	2-(N-pyrrolidinylmethyl)phenyl
7.	H	1-methyl-2-imidazolyl
8.	H	2-methyl-1-imidazolyl
9.	H	2-(dimethylaminomethyl)-1-imidazolyl
10.	H	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
11.	H	2-(N-(cyclobutyl)-aminomethyl)phenyl
12.	H	2-(N-(cyclopentyl)-aminomethyl)phenyl

13.	H	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
14.	H	2-(isopropylaminomethyl)phenyl
15.	H	4-azabenzimidazol-1-yl
16.	H	5-azabenzimidazol-1-yl
17.	H	6-azabenzimidazol-1-yl
18.	H	7-azabenzimidazol-1-yl
19.	CH ₃	2-(aminosulfonyl)phenyl
20.	CH ₃	2-(methylaminosulfonyl)phenyl
21.	CH ₃	1-pyrrolidinocarbonyl
22.	CH ₃	2-(methylsulfonyl)phenyl
23.	CH ₃	2-(N,N-dimethylaminomethyl)phenyl
24.	CH ₃	2-(N-pyrrolidinylmethyl)phenyl
25.	CH ₃	1-methyl-2-imidazolyl
26.	CH ₃	2-methyl-1-imidazolyl
27.	CH ₃	2-(dimethylaminomethyl)-1-imidazolyl
28.	CH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
29.	CH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
30.	CH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
31.	CH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
32.	CH ₃	2-(isopropylaminomethyl)phenyl
33.	CH ₃	4-azabenzimidazol-1-yl
34.	CH ₃	5-azabenzimidazol-1-yl
35.	CH ₃	6-azabenzimidazol-1-yl
36.	CH ₃	7-azabenzimidazol-1-yl
37.	CH ₂ CH ₃	2-(aminosulfonyl)phenyl
38.	CH ₂ CH ₃	2-(methylaminosulfonyl)phenyl
39.	CH ₂ CH ₃	1-pyrrolidinocarbonyl
40.	CH ₂ CH ₃	2-(methylsulfonyl)phenyl
41.	CH ₂ CH ₃	2-(N,N-dimethylaminomethyl)phenyl
42.	CH ₂ CH ₃	2-(N-pyrrolidinylmethyl)phenyl
43.	CH ₂ CH ₃	1-methyl-2-imidazolyl
44.	CH ₂ CH ₃	2-methyl-1-imidazolyl
45.	CH ₂ CH ₃	2-(dimethylaminomethyl)-1-imidazolyl
46.	CH ₂ CH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
47.	CH ₂ CH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
48.	CH ₂ CH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
49.	CH ₂ CH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
50.	CH ₂ CH ₃	2-(isopropylaminomethyl)phenyl
51.	CH ₂ CH ₃	4-azabenzimidazol-1-yl
52.	CH ₂ CH ₃	5-azabenzimidazol-1-yl
53.	CH ₂ CH ₃	6-azabenzimidazol-1-yl
54.	CH ₂ CH ₃	7-azabenzimidazol-1-yl
55.	CF ₃	2-(aminosulfonyl)phenyl
56.	CF ₃	2-(methylaminosulfonyl)phenyl
57.	CF ₃	1-pyrrolidinocarbonyl
58.	CF ₃	2-(methylsulfonyl)phenyl

59.	CF3	2-(N,N-dimethylaminomethyl)phenyl
60.	CF3	2-(N-pyrrolidinylmethyl)phenyl
61.	CF3	1-methyl-2-imidazolyl
62.	CF3	2-methyl-1-imidazolyl
63.	CF3	2-(dimethylaminomethyl)-1-imidazolyl
64.	CF3	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
65.	CF3	2-(N-(cyclobutyl)-aminomethyl)phenyl
66.	CF3	2-(N-(cyclopentyl)-aminomethyl)phenyl
67.	CF3	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
68.	CF3	2-(isopropylaminomethyl)phenyl
69.	CF3	4-azabenzimidazol-1-yl
70.	CF3	5-azabenzimidazol-1-yl
71.	CF3	6-azabenzimidazol-1-yl
72.	CF3	7-azabenzimidazol-1-yl
73.	SCH3	2-(aminosulfonyl)phenyl
74.	SCH3	2-(methylaminosulfonyl)phenyl
75.	SCH3	1-pyrrolidinocarbonyl
76.	SCH3	2-(methylsulfonyl)phenyl
77.	SCH3	2-(N,N-dimethylaminomethyl)phenyl
78.	SCH3	2-(N-pyrrolidinylmethyl)phenyl
79.	SCH3	1-methyl-2-imidazolyl
80.	SCH3	2-methyl-1-imidazolyl
81.	SCH3	2-(dimethylaminomethyl)-1-imidazolyl
82.	SCH3	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
83.	SCH3	2-(N-(cyclobutyl)-aminomethyl)phenyl
84.	SCH3	2-(N-(cyclopentyl)-aminomethyl)phenyl
85.	SCH3	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
86.	SCH3	2-(isopropylaminomethyl)phenyl
87.	SCH3	4-azabenzimidazol-1-yl
88.	SCH3	5-azabenzimidazol-1-yl
89.	SCH3	6-azabenzimidazol-1-yl
90.	SCH3	7-azabenzimidazol-1-yl
91.	SOCH3	2-(aminosulfonyl)phenyl
92.	SOCH3	2-(methylaminosulfonyl)phenyl
93.	SOCH3	1-pyrrolidinocarbonyl
94.	SOCH3	2-(methylsulfonyl)phenyl
95.	SOCH3	2-(N,N-dimethylaminomethyl)phenyl
96.	SOCH3	2-(N-pyrrolidinylmethyl)phenyl
97.	SOCH3	1-methyl-2-imidazolyl
98.	SOCH3	2-methyl-1-imidazolyl
99.	SOCH3	2-(dimethylaminomethyl)-1-imidazolyl
100.	SOCH3	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
101.	SOCH3	2-(N-(cyclobutyl)-aminomethyl)phenyl
102.	SOCH3	2-(N-(cyclopentyl)-aminomethyl)phenyl
103.	SOCH3	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
104.	SOCH3	2-(isopropylaminomethyl)phenyl







105.	SOCH ₃	4-azabenzimidazol-1-yl
106.	SOCH ₃	5-azabenzimidazol-1-yl
107.	SOCH ₃	6-azabenzimidazol-1-yl
108.	SOCH ₃	7-azabenzimidazol-1-yl
109.	SO ₂ CH ₃	2-(aminosulfonyl)phenyl
110.	SO ₂ CH ₃	2-(methylaminosulfonyl)phenyl
111.	SO ₂ CH ₃	1-pyrrolidinocarbonyl
112.	SO ₂ CH ₃	2-(methylsulfonyl)phenyl
113.	SO ₂ CH ₃	2-(N,N-dimethylaminomethyl)phenyl
114.	SO ₂ CH ₃	2-(N-pyrrolidinylmethyl)phenyl
115.	SO ₂ CH ₃	1-methyl-2-imidazolyl
116.	SO ₂ CH ₃	2-methyl-1-imidazolyl
117.	SO ₂ CH ₃	2-(dimethylaminomethyl)-1-imidazolyl
118.	SO ₂ CH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
119.	SO ₂ CH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
120.	SO ₂ CH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
121.	SO ₂ CH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
122.	SO ₂ CH ₃	2-(isopropylaminomethyl)phenyl
123.	SO ₂ CH ₃	4-azabenzimidazol-1-yl
124.	SO ₂ CH ₃	5-azabenzimidazol-1-yl
125.	SO ₂ CH ₃	6-azabenzimidazol-1-yl
126.	SO ₂ CH ₃	7-azabenzimidazol-1-yl
127.	Cl	2-(aminosulfonyl)phenyl
128.	Cl	2-(methylaminosulfonyl)phenyl
129.	Cl	1-pyrrolidinocarbonyl
130.	Cl	2-(methylsulfonyl)phenyl
131.	Cl	2-(N,N-dimethylaminomethyl)phenyl
132.	Cl	2-(N-pyrrolidinylmethyl)phenyl
133.	Cl	1-methyl-2-imidazolyl
134.	Cl	2-methyl-1-imidazolyl
135.	Cl	2-(dimethylaminomethyl)-1-imidazolyl
136.	Cl	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
137.	Cl	2-(N-(cyclobutyl)-aminomethyl)phenyl
138.	Cl	2-(N-(cyclopentyl)-aminomethyl)phenyl
139.	Cl	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
140.	Cl	2-(isopropylaminomethyl)phenyl
141.	Cl	4-azabenzimidazol-1-yl
142.	Cl	5-azabenzimidazol-1-yl
143.	Cl	6-azabenzimidazol-1-yl
144.	Cl	7-azabenzimidazol-1-yl
145.	F	2-(aminosulfonyl)phenyl
146.	F	2-(methylaminosulfonyl)phenyl
147.	F	1-pyrrolidinocarbonyl
148.	F	2-(methylsulfonyl)phenyl
149.	F	2-(N,N-dimethylaminomethyl)phenyl
150.	F	2-(N-pyrrolidinylmethyl)phenyl

151.	F	1-methyl-2-imidazolyl
152.	F	2-methyl-1-imidazolyl
153.	F	2-(dimethylaminomethyl)-1-imidazolyl
154.	F	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
155.	F	2-(N-(cyclobutyl)-aminomethyl)phenyl
156.	F	2-(N-(cyclopentyl)-aminomethyl)phenyl
157.	F	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
158.	F	2-(isopropylaminomethyl)phenyl
159.	F	4-azabenzimidazol-1-yl
160.	F	5-azabenzimidazol-1-yl
161.	F	6-azabenzimidazol-1-yl
162.	F	7-azabenzimidazol-1-yl
163.	CO ₂ CH ₃	2-(N-pyrrolidinylmethyl)phenyl
164.	CO ₂ CH ₃	1-methyl-2-imidazolyl
165.	CO ₂ CH ₃	2-methyl-1-imidazolyl
166.	CO ₂ CH ₃	2-(dimethylaminomethyl)-1-imidazolyl
167.	CO ₂ CH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
168.	CO ₂ CH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
169.	CO ₂ CH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
170.	CO ₂ CH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
171.	CO ₂ CH ₃	2-(isopropylaminomethyl)phenyl
172.	CO ₂ CH ₃	4-azabenzimidazol-1-yl
173.	CO ₂ CH ₃	5-azabenzimidazol-1-yl
174.	CO ₂ CH ₃	6-azabenzimidazol-1-yl
175.	CO ₂ CH ₃	7-azabenzimidazol-1-yl
176.	CH ₂ OCH ₃	2-(aminosulfonyl)phenyl
177.	CH ₂ OCH ₃	2-(methylaminosulfonyl)phenyl
178.	CH ₂ OCH ₃	1-pyrrolidinocarbonyl
179.	CH ₂ OCH ₃	2-(methylsulfonyl)phenyl
180.	CH ₂ OCH ₃	2-(N,N-dimethylaminomethyl)phenyl
181.	CH ₂ OCH ₃	2-(N-pyrrolidinylmethyl)phenyl
182.	CH ₂ OCH ₃	1-methyl-2-imidazolyl
183.	CH ₂ OCH ₃	2-methyl-1-imidazolyl
184.	CH ₂ OCH ₃	2-(dimethylaminomethyl)-1-imidazolyl
185.	CH ₂ OCH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
186.	CH ₂ OCH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
187.	CH ₂ OCH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
188.	CH ₂ OCH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
189.	CH ₂ OCH ₃	2-(isopropylaminomethyl)phenyl
190.	CH ₂ OCH ₃	4-azabenzimidazol-1-yl
191.	CH ₂ OCH ₃	5-azabenzimidazol-1-yl
192.	CH ₂ OCH ₃	6-azabenzimidazol-1-yl
193.	CH ₂ OCH ₃	7-azabenzimidazol-1-yl
194.	CONH ₂	2-(aminosulfonyl)phenyl
195.	CONH ₂	2-(methylaminosulfonyl)phenyl
196.	CONH ₂	1-pyrrolidinocarbonyl

197.	CONH2	2-(methylsulfonyl)phenyl
198.	CONH2	2-(N,N-dimethylaminomethyl)phenyl
199.	CONH2	2-(N-pyrrolidinylmethyl)phenyl
200.	CONH2	1-methyl-2-imidazolyl
201.	CONH2	2-methyl-1-imidazolyl
202.	CONH2	2-(dimethylaminomethyl)-1-imidazolyl
203.	CONH2	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
204.	CONH2	2-(N-(cyclobutyl)-aminomethyl)phenyl
205.	CONH2	2-(N-(cyclopentyl)-aminomethyl)phenyl
206.	CONH2	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
207.	CONH2	2-(isopropylaminomethyl)phenyl
208.	CONH2	4-azabenzimidazol-1-yl
209.	CONH2	5-azabenzimidazol-1-yl
210.	CONH2	6-azabenzimidazol-1-yl
211.	CONH2	7-azabenzimidazol-1-yl
212.	CN	2-(aminosulfonyl)phenyl
213.	CN	2-(methylaminosulfonyl)phenyl
214.	CN	1-pyrrolidinocarbonyl
215.	CN	2-(methylsulfonyl)phenyl
216.	CN	2-(N,N-dimethylaminomethyl)phenyl
217.	CN	2-(N-pyrrolidinylmethyl)phenyl
218.	CN	1-methyl-2-imidazolyl
219.	CN	2-methyl-1-imidazolyl
220.	CN	2-(dimethylaminomethyl)-1-imidazolyl
221.	CN	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
222.	CN	2-(N-(cyclobutyl)-aminomethyl)phenyl
223.	CN	2-(N-(cyclopentyl)-aminomethyl)phenyl
224.	CN	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
225.	CN	2-(isopropylaminomethyl)phenyl
226.	CN	4-azabenzimidazol-1-yl
227.	CN	5-azabenzimidazol-1-yl
228.	CN	6-azabenzimidazol-1-yl
229.	CN	7-azabenzimidazol-1-yl
230.	CH2NH2	2-(N-pyrrolidinylmethyl)phenyl
231.	CH2NH2	1-methyl-2-imidazolyl
232.	CH2NH2	2-methyl-1-imidazolyl
233.	CH2NH2	2-(dimethylaminomethyl)-1-imidazolyl
234.	CH2NH2	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
235.	CH2NH2	2-(N-(cyclobutyl)-aminomethyl)phenyl
236.	CH2NH2	2-(N-(cyclopentyl)-aminomethyl)phenyl
237.	CH2NH2	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
238.	CH2NH2	2-(isopropylaminomethyl)phenyl
239.	CH2NH2	4-azabenzimidazol-1-yl
240.	CH2NH2	5-azabenzimidazol-1-yl
241.	CH2NH2	6-azabenzimidazol-1-yl
242.	CH2NH2	7-azabenzimidazol-1-yl

243.	CH ₂ NHSO ₂ CH ₃	2-(aminosulfonyl)phenyl
244.	CH ₂ NHSO ₂ CH ₃	2-(methyaminosulfonyl)phenyl
245.	CH ₂ NHSO ₂ CH ₃	1-pyrrolidinocarbonyl
246.	CH ₂ NHSO ₂ CH ₃	2-(methylsulfonyl)phenyl
247.	CH ₂ NHSO ₂ CH ₃	2-(N,N-dimethylaminomethyl)phenyl
248.	CH ₂ NHSO ₂ CH ₃	2-(N-pyrrolidinylmethyl)phenyl
249.	CH ₂ NHSO ₂ CH ₃	1-methyl-2-imidazolyl
250.	CH ₂ NHSO ₂ CH ₃	2-methyl-1-imidazolyl
251.	CH ₂ NHSO ₂ CH ₃	2-(dimethylaminomethyl)-1-imidazolyl
252.	CH ₂ NHSO ₂ CH ₃	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
253.	CH ₂ NHSO ₂ CH ₃	2-(N-(cyclobutyl)-aminomethyl)phenyl
254.	CH ₂ NHSO ₂ CH ₃	2-(N-(cyclopentyl)-aminomethyl)phenyl
255.	CH ₂ NHSO ₂ CH ₃	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
256.	CH ₂ NHSO ₂ CH ₃	2-(isopropylaminomethyl)phenyl
257.	CH ₂ NHSO ₂ CH ₃	4-azabenzimidazol-1-yl
258.	CH ₂ NHSO ₂ CH ₃	5-azabenzimidazol-1-yl
259.	CH ₂ NHSO ₂ CH ₃	6-azabenzimidazol-1-yl
260.	CH ₂ NHSO ₂ CH ₃	7-azabenzimidazol-1-yl

Table 2




5

Ex#	B
261.	2-(aminosulfonyl)phenyl
262.	2-(methylaminosulfonyl)phenyl
263.	1-pyrrolidinocarbonyl
264.	2-(methylsulfonyl)phenyl
265.	2-(N,N-dimethylaminomethyl)phenyl
266.	2-(N-pyrrolidinylmethyl)phenyl
267.	1-methyl-2-imidazolyl
268.	2-methyl-1-imidazolyl
269.	2-(dimethylaminomethyl)-1-imidazolyl
270.	2-(N-(cyclopropyl-methyl)aminomethyl)phenyl
271.	2-(N-(cyclobutyl)-aminomethyl)phenyl
272.	2-(N-(cyclopentyl)-aminomethyl)phenyl
273.	2-(N-(3-hydroxypyrrolidinyl)-methyl)phenyl
274.	2-(isopropylaminomethyl)phenyl
275.	4-azabenzimidazol-1-yl
276.	5-azabenzimidazol-1-yl
277.	6-azabenzimidazol-1-yl
278.	7-azabenzimidazol-1-yl

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced
5 otherwise that as specifically described herein.

WHAT IS CLAIMED IS:

1. A compound of formula Ia, Ib, Ic, or Id:



5 or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;

D is selected from $C(=NR^8)NR^7R^9$, $C(O)NR^7R^8$, NR^7R^8 , and $CH_2NR^7R^8$, provided that D is substituted meta or para to
10 ring M on E;

E is phenyl substituted with 1 R or pyridyl substituted with 1 R;

15 R is selected from H, Cl, F, OR^3 , CH_3 , CH_2CH_3 , OCF_3 , and CF_3 ;

Z is selected from $C(O)$, $CH_2C(O)$, $C(O)CH_2$, $NHC(O)$, and $C(O)NH$, provided that Z does not form a N-N bond with group A;

20

R^{1a} is selected from H, $-(CH_2)_r-R^{1'}$, $-CH=CH-R^{1'}$, $NCH_2R^{1''}$, $OCH_2R^{1''}$, $SCH_2R^{1''}$, $NH(CH_2)_2(CH_2)_tR^{1'}$, $O(CH_2)_2(CH_2)_tR^{1'}$, and $S(CH_2)_2(CH_2)_tR^{1'}$;

25 $R^{1'}$ is selected from H, C_{1-3} alkyl, F, Cl, Br, I, $-CN$, $-CHO$, $(CF_2)_rCF_3$, $(CH_2)_rOR^2$, NR^2R^{2a} , $C(O)R^{2c}$, $OC(O)R^2$, $(CF_2)_rCO_2R^{2c}$, $S(O)_pR^{2b}$, $NR^2(CH_2)_rOR^2$, $CH(=NR^{2c})NR^2R^{2a}$, $NR^2C(O)R^{2b}$, $NR^2C(O)NHR^{2b}$, $NR^2C(O)_2R^{2a}$, $OC(O)NR^{2a}R^{2b}$, $C(O)NR^2R^{2a}$, $C(O)NR^2(CH_2)_rOR^2$, $SO_2NR^2R^{2a}$, $NR^2SO_2R^{2b}$, C_{3-6}
30 carbocyclic residue substituted with 0-2 R^{4a} , and 5-10

membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a} ;

- 5 $R^{1''}$ is selected from H, $CH(CH_2OR^2)_2$, $C(O)R^{2c}$, $C(O)NR^{2a}$, $S(O)R^{2b}$, $S(O)_2R^{2b}$, and SO_2NR^{2a} ;

- 10 R^2 , at each occurrence, is selected from H, CF_3 , C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , a C_{3-6} carbocyclic- CH_2 - residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

- 15 R^{2a} , at each occurrence, is selected from H, CF_3 , C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

- 20 R^{2b} , at each occurrence, is selected from CF_3 , C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

- 25 R^{2c} , at each occurrence, is selected from CF_3 , OH, C_{1-4} alkoxy, C_{1-6} alkyl, benzyl, C_{3-6} carbocyclic residue substituted with 0-2 R^{4b} , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4b} ;

- 30 alternatively, R^2 and R^{2a} , together with the atom to which they are attached, combine to form a 5 or 6 membered
- 35

saturated, partially saturated or unsaturated ring substituted with 0-2 R^{4b} and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

5

R^3 , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

R^{3a} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

10

R^{3b} , at each occurrence, is selected from H, C_{1-4} alkyl, and phenyl;

15 R^{3c} , at each occurrence, is selected from C_{1-4} alkyl, and phenyl;

A is selected from:

C_{3-10} carbocyclic residue substituted with 0-2 R^4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^4 ;

20

B is selected from:

$X-Y$, NR^2R^{2a} , $C(=NR^2)NR^2R^{2a}$, $NR^2C(=NR^2)NR^2R^{2a}$, C_{3-10} carbocyclic residue substituted with 0-2 R^{4a} , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R^{4a} ;

30

X is selected from C_{1-4} alkylene, $-CR^2(CR^2R^{2b})(CH_2)_t-$, $-C(O)-$, $-C(=NR^1)-$, $-CR^2(NR^1R^2)-$, $-CR^2(OR^2)-$, $-CR^2(SR^2)-$, $-C(O)CR^2R^{2a}-$, $-CR^2R^{2a}C(O)-$, $-S(O)_p-$, $-S(O)_pCR^2R^{2a}-$, $-CR^2R^{2a}S(O)_p-$, $-S(O)_2NR^2-$, $-NR^2S(O)_2-$, $-NR^2S(O)_2CR^2R^{2a}-$, $-CR^2R^{2a}S(O)_2NR^2-$, $-NR^2S(O)_2NR^2-$, $-C(O)NR^2-$, $-NR^2C(O)-$,

35

-C(O)NR²CR²R^{2a}-, -NR²C(O)CR²R^{2a}-, -CR²R^{2a}C(O)NR²-,
 -CR²R^{2a}NR²C(O)-, -NR²C(O)O-, -OC(O)NR²-, -NR²C(O)NR²-,
 -NR²-, -NR²CR²R^{2a}-, -CR²R^{2a}NR²-, O, -CR²R^{2a}O-, and
 -OCR²R^{2a}-;

5

Y is selected from:

(CH₂)_rNR²R^{2a}, provided that X-Y do not form a N-N, O-N,
 or S-N bond,

C₃₋₁₀ carbocyclic residue substituted with 0-2 R^{4a}, and

10

5-10 membered heterocyclic system containing from 1-4
 heteroatoms selected from the group consisting of N, O, and
 S substituted with 0-2 R^{4a};

R⁴, at each occurrence, is selected from H, =O, (CH₂)_rOR², F,

15

Cl, Br, I, C₁₋₄ alkyl, -CN, NO₂, (CH₂)_rNR²R^{2a},
 (CH₂)_rC(O)R^{2c}, NR²C(O)R^{2b}, C(O)NR²R^{2a}, NR²C(O)NR²R^{2a},
 CH(=NR²)NR²R^{2a}, CH(=NS(O)₂R⁵)NR²R^{2a}, NHC(=NR²)NR²R^{2a},
 C(O)NHC(=NR²)NR²R^{2a}, SO₂NR²R^{2a}, NR²SO₂NR²R^{2a}, NR²SO₂-C₁₋₄
 alkyl, NR²SO₂R⁵, S(O)_pR⁵, (CF₂)_rCF₃, NCH₂R^{1''}, OCH₂R^{1''},
 SCH₂R^{1''}, N(CH₂)₂(CH₂)_tR^{1'}, (CH₂)₂(CH₂)_tR^{1'}, and
 S(CH₂)₂(CH₂)_tR^{1'};

20

alternatively, one R⁴ is a 5-6 membered aromatic heterocycle
 containing from 1-4 heteroatoms selected from the group
 consisting of N, O, and S;

25

R^{4a}, at each occurrence, is selected from H, =O, (CH₂)_rOR²,

(CH₂)_r-F, (CH₂)_r-Br, (CH₂)_r-Cl, Cl, Br, F, I, C₁₋₄ alkyl,
 -CN, NO₂, (CH₂)_rNR²R^{2a}, (CH₂)_rC(O)R^{2c}, NR²C(O)R^{2b},
 C(O)NR²R^{2a}, C(O)NH(CH₂)₂NR²R^{2a}, NR²C(O)NR²R^{2a},
 CH(=NR²)NR²R^{2a}, NHC(=NR²)NR²R^{2a}, SO₂NR²R^{2a}, NR²SO₂NR²R^{2a},
 NR²SO₂-C₁₋₄ alkyl, C(O)NHSO₂-C₁₋₄ alkyl, NR²SO₂R⁵, S(O)_pR⁵,
 and (CF₂)_rCF₃;

30

alternatively, one R^{4a} is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R^5 ;

5 R^{4b} , at each occurrence, is selected from H, =O, $(CH_2)_rOR^3$, F, Cl, Br, I, C_{1-4} alkyl, -CN, NO_2 , $(CH_2)_rNR^3R^{3a}$, $(CH_2)_rC(O)R^3$, $(CH_2)_rC(O)OR^{3c}$, $NR^3C(O)R^{3a}$, $C(O)NR^3R^{3a}$, $NR^3C(O)NR^3R^{3a}$, $CH(=NR^3)NR^3R^{3a}$, $NR^3C(=NR^3)NR^3R^{3a}$, $SO_2NR^3R^{3a}$, $NR^3SO_2NR^3R^{3a}$, $NR^3SO_2-C_{1-4}$ alkyl, $NR^3SO_2CF_3$, NR^3SO_2 -phenyl, $S(O)_pCF_3$, $S(O)_p-C_{1-4}$ alkyl, $S(O)_p$ -phenyl, and $(CF_2)_rCF_3$;

10

R^5 , at each occurrence, is selected from CF_3 , C_{1-6} alkyl, phenyl substituted with 0-2 R^6 , and benzyl substituted with 0-2 R^6 ;

15

R^6 , at each occurrence, is selected from H, OH, $(CH_2)_rOR^2$, halo, C_{1-4} alkyl, -CN, NO_2 , $(CH_2)_rNR^2R^{2a}$, $(CH_2)_rC(O)R^{2b}$, $NR^2C(O)R^{2b}$, $NR^2C(O)NR^2R^{2a}$, $CH(=NH)NH_2$, $NHC(=NH)NH_2$, $SO_2NR^2R^{2a}$, $NR^2SO_2NR^2R^{2a}$, and $NR^2SO_2C_{1-4}$ alkyl;

20

R^7 , at each occurrence, is selected from H, OH, C_{1-6} alkyl, C_{1-6} alkylcarbonyl, C_{1-6} alkoxy, C_{1-4} alkoxycarbonyl, $(CH_2)_n$ -phenyl, C_{6-10} aryloxy, C_{6-10} aryloxycarbonyl, C_{6-10} arylmethylcarbonyl, C_{1-4} alkylcarbonyloxy C_{1-4} alkoxy carbonyl, C_{6-10} arylcarbonyloxy C_{1-4} alkoxy carbonyl, C_{1-6} alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C_{1-4} alkoxycarbonyl;

25

R^8 , at each occurrence, is selected from H, C_{1-6} alkyl and $(CH_2)_n$ -phenyl;

30

alternatively, R^7 and R^8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;

35

R⁹, at each occurrence, is selected from H, C₁₋₆ alkyl and (CH₂)_n-phenyl;

5 n, at each occurrence, is selected from 0, 1, 2, and 3;

m, at each occurrence, is selected from 0, 1, and 2;

p, at each occurrence, is selected from 0, 1, and 2;

10

r, at each occurrence, is selected from 0, 1, 2, and 3;

s, at each occurrence, is selected from 0, 1, and 2; and,

15 t, at each occurrence, is selected from 0, 1, 2, and 3.

2. A compound according to Claim 1, wherein the compound is of formula Ic or Id;

20 A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R⁴; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, 25 thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, 30 benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;

35

B is selected from: H, Y, X-Y;


X is selected from C₁₋₄ alkylene, -C(O)-, -C(=NR)-,
 -CR²(NR²R^{2a})-, -C(O)CR²R^{2a}-, -CR²R^{2a}C(O), -C(O)NR²-,
 5 -NR²C(O)-, -C(O)NR²CR²R^{2a}-, -NR²C(O)CR²R^{2a}-,
 -CR²R^{2a}C(O)NR²-, -CR²R^{2a}NR²C(O)-, -NR²C(O)NR²-, -NR²-,
 -NR²CR²R^{2a}-, -CR²R^{2a}NR²-, O, -CR²R^{2a}O-, and -OCR²R^{2a}-;

Y is NR²R^{2a}, provided that X-Y do not form a N-N or O-N bond;

alternatively, Y is selected from one of the following
 carbocyclic and heterocyclic systems which are
 substituted with 0-2 R^{4a};

cyclopropyl, cyclopentyl, cyclohexyl, phenyl,
 15 piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl,
 morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl,
 oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl,
 isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,
 thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl,
 20 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,
 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl,
 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,
 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl,
 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl,
 25 benzothiofuranyl, indolyl, benzimidazolyl,
 benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,
 benzisothiazolyl, and isoindazolyl;

alternatively, Y is selected from the following bicyclic
 heteroaryl ring systems:



K is selected from O, S, NH, and N; and,

5 s is 0.

3. A compound according to Claim 2, wherein;

10 E is phenyl substituted with R or 2-pyridyl substituted with R;

R is selected from H, Cl, F, OCH₃, CH₃, OCF₃, and CF₃;

15 Z is selected from a C(O)CH₂ and C(O)NH, provided that Z does not form a N-N bond with group A;

20 R^{1a} is selected from H, CH₃, CH₂CH₃, Cl, F, CF₃, OCH₃, NR²R^{2a}, S(O)_pR^{2b}, CH₂S(O)_pR^{2b}, CH₂NR²S(O)_pR^{2b}, C(O)R^{2c}, CH₂C(O)R^{2c}, C(O)NR²R^{2a}, and SO₂NR²R^{2a};

A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R⁴; and,

25 B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R^{4a};

R², at each occurrence, is selected from H, CH₃, CH₂CH₃, cyclopropylmethyl, cyclobutyl, and cyclopentyl;

R^{2a} , at each occurrence, is H or CH_3 ;

alternatively, R^2 and R^{2a} , together with the atom to which
 5 they are attached, combine to form pyrrolidine
 substituted with 0-2 R^{4b} ;

R^4 , at each occurrence, is selected from OH, $(CH_2)_rOR^2$, halo,
 C_{1-4} alkyl, $(CH_2)_rNR^2R^{2a}$, and $(CF_2)_rCF_3$;

10 R^{4a} is selected from C_{1-4} alkyl, CF_3 , $(CH_2)_rOR^2$, $(CH_2)_rNR^2R^{2a}$,
 $S(O)_pR^5$, $SO_2NR^2R^{2a}$, and 1- CF_3 -tetrazol-2-yl;

R^{4b} , at each occurrence, is selected from H, CH_3 , and OH;

15 R^5 , at each occurrence, is selected from CF_3 , C_{1-6} alkyl,
 phenyl, and benzyl;

X is CH_2 or $C(O)$;

20 Y is selected from pyrrolidino and morpholino; and,

r, at each occurrence, is selected from 0, 1, and 2.

25 4. A compound according to Claim 3, wherein;

R^{1a} is absent or is selected from H, CH_3 , CH_2CH_3 , Cl, F, CF_3 ,
 OCH_3 , NR^2R^{2a} , $S(O)_pR^{2b}$, $C(O)NR^2R^{2a}$, $CH_2S(O)_pR^{2b}$, $CH_2NR^2S(O)_pR^{2b}$,
 $C(O)R^{2c}$, $CH_2C(O)R^{2c}$, and $SO_2NR^2R^{2a}$;

30 A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl,
 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-
 phenyl, 2-methylphenyl, 2-aminophenyl, and 2-
 methoxyphenyl; and,

B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

5. A compound according to Claim 1, wherein the compound is selected from the group:

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-aminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylsulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylaminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N,N-dimethylaminosulfonyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N-pyrrolidinomethyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N-(3"-hydroxypyrrolidino)methyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-aminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

5 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylsulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

10 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-methylaminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

15 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-N,N-dimethylaminosulfonyl-2-fluoro-[1,1']-biphen-4-yl))carboxamide;

20 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2-fluoro-2'-N-pyrrolidinomethyl-[1,1']-biphen-4-yl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2-fluoro-2'-N-(3"-hydroxypyrrolidino)methyl-[1,1']-biphen-4-yl))carboxamide;

25 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(pyrrolidinocarbonyl)phenyl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(1"-methylimidazol-2"-yl)phenyl))carboxamide;

30 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(2"-methylimidazolyl)phenyl))carboxamide;

35 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(4'-(2"-N,N-dimethylamino)imidazolyl)phenyl))carboxamide;

1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(pyrrolidinocarbonyl)phenyl))carboxamide;

5 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(1"-methylimidazol-2"-
yl)phenyl))carboxamide;

10 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(2"-methylimidazolyl)phenyl))carboxamide;
and,

15 1-(3-(aminomethyl)phenyl)-3-cyano-1H-pyrazole-5-(N-(2'-
fluoro-4'-(2"-(N,N-
dimethylamino)imidazolyl)phenyl))carboxamide;

or a pharmaceutically acceptable salt form thereof.

20 6. A pharmaceutical composition, comprising: a
pharmaceutically acceptable carrier and a therapeutically
effective amount of a compound of Claim 1, 2, 3, 4, or 5 or
a pharmaceutically acceptable salt form thereof.

25 7. A method for treating or preventing a thromboembolic
disorder, comprising: administering to a patient in need
thereof a therapeutically effective amount of a compound of
Claim 1, 2, 3, 4, or 5 or a pharmaceutically acceptable salt
form thereof.

30 8. A compound of Claim 1, 2, 3, 4, or 5 for use in
therapy.

35 9. Use of a compound of Claim 1, 2, 3, 4, or 5 for the
manufacture of a medicament for the treatment of a
thromboembolic disorder.

INTERNATIONAL SEARCH REPORT

In. ational Application No

PCT/US 00/30209

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D231/14 A61P7/02 C07D401/12 C07D249/10 C07D403/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 57937 A (DU PONT MERCK PHARMA) 23 December 1998 (1998-12-23) cited in the application R1a is -(CH2)r-R1' where R is zero and R1' is CN. M is p, t or w. claim 1 ---	1-9
X	WO 99 32454 A (DU PONT PHARM CO) 1 July 1999 (1999-07-01) cited in the application R1a is -(CH2)r-R1' where R is zero and R1' is CN. page 10; claims 1,2 ---	1-9
X	WO 98 28269 A (DU PONT MERCK PHARMA) 2 July 1998 (1998-07-02) cited in the application claims 1,2 -----	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 February 2001

Date of mailing of the international search report

27.02.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

INTERNATIONAL SEARCH REPORT

international application No.
PCT/US 00/30209

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 7 is directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-4, 6-9 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a selection of the compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formulae Ic and Id. The compounds of the formulae Ia and Ib are not exemplified and are not considered to be recognised homologues, analogues or equivalents of Ic and Id. Accordingly Ia and Ib have not been searched.

It is further noted that in all of the examples Z is always $-C(=O)NH-$. Accordingly only compounds containing this feature have been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

I. International Application No

PCT/US 00/30209

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9857937 A	23-12-1998	AU 8150398 A	04-01-1999
		BR 9810151 A	08-08-2000
		EP 0991625 A	12-04-2000
		HR 980334 A	30-04-1999
		LT 99146 A, B	25-05-2000
		LV 12516 A	20-07-2000
		NO 996316 A	17-12-1999
		PL 337831 A	11-09-2000
		SI 20208 A	31-10-2000
		SK 174699 A	14-08-2000
		US 5998424 A	07-12-1999
WO 9932454 A	01-07-1999	AU 1724499 A	12-07-1999
		BR 9813835 A	10-10-2000
		EP 1042299 A	11-10-2000
WO 9828269 A	02-07-1998	AU 5602098 A	17-07-1998
		CN 1246847 A	08-03-2000
		EP 0946508 A	06-10-1999
		HR 970698 A	31-10-1998
		LT 99076 A, B	25-02-2000
		LV 12430 A	20-02-2000
		LV 12430 B	20-07-2000
		NO 992633 A	20-08-1999
		PL 334250 A	14-02-2000
		SI 20017 A	29-02-2000
		US 6020357 A	01-02-2000
		BR 9714073 A	09-05-2000